Clinical results of iridium-192 high dose rate brachytherapy with external beam radiotherapy

Japanese Journal of Clinical Oncology

Volumn 40, Issue 7, 2010, Pages 677-683

  Nohara, Takahiro ^a   Mizokami, Atsushi ^a   Kumano, Tomoyasu ^a   Shigehara, Kazuyoshi ^a   Konaka, Hiroyuki ^a   Yoshifumi, Kadono ^a   Yasuhide, Kitagawa ^a   Izumi, Kouji ^a   Narimoto, Kazutaka ^a   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

High dose rate brachytherapy; Prostate cancer

Indexed keywords

IRIDIUM 192;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DELIRIUM; DIARRHEA; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERITONEAL DISEASE; PERONEUS NERVE PARALYSIS; POLLAKISURIA; PROCTITIS; PROSTATE CANCER; SEXUAL SATISFACTION; SURVIVAL RATE; SURVIVAL TIME; URETHRA STRICTURE; URINE RETENTION;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOISOTOPE TELETHERAPY; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 77954454747     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq016     Document Type: Article

References (35)

1. Wakai K. Descriptive epidemiology of prostate cancer in Japan and Western countries. Nippon Rinsho 2005;63:207-12.
2. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D, et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001;166:2185-8.
3. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. JUrol2002;167:528-34.
4. Dubbelman YD, Dohle GR, Schroder FH. Sexual function before and after radical retropubic prostatectomy: a systematic review of prognostic indicators for a successful outcome. Eur Urol 2006;50:711-8; discussion 8-20.
5. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 2007;177:2151-6; discussion 6.
6. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003;8:474-87.
7. Joly F,Alibhai SM,Galica J,Park A,Yi QL,Wagner L,et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol 2006;176:2443-7.
8. Kumar RJ, Barqawi A, Crawford ED. Preventing and treating the complications of hormone therapy. Curr Urol Rep 2005;6:217-23.
9. Akaza H, Homma Y, Usami M, Hirao Y, Tsushima T, Okada K, et al. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int 2006;9:573-9.
10. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥ Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33.
11. Whitmore WF Jr, Hilaris B, Grabstald H. Retropubic implantation to iodine 125 in the treatment of prostatic cancer. J Urol 1972;108:918-20.
12. Ravery V. Brachytherapy versus radical prostatectomy. BJU Int 2001;87:141-3.
13. Yorozu A, Toya K, Ohashi T, Ohsuga K, Ito R, Kasamatsu T, et al. Brachytherapy for prostate cancer. Gan To Kagaku Ryoho 2006;33:424-7.
14. Williams SG, Taylor JM, Liu N, Tra Y, Duchesne GM, Kestin LL, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007;68:24-33.
15. Wang JZ, Li XA, Yu CX, DiBiase SJ. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us? Int J Radiat Oncol Biol Phys 2003;57:1101-8.
16. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;5:6-13.
17. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50:1021-31.
18. Shigehara K, Mizokami A, Komatsu K, Koshida K, Namiki M. Four year clinical statistics of iridium-192 high dose rate brachytherapy. Int J Urol 2006;13:116-21.
19. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
20. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
21. Roach M, 3rd, Hanks G, Thames H, Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
22. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
23. Astrom L, Pedersen D, Mercke C, Holmang S, Johansson KA. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 2005;74:157-61.
24. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005;61:1306-16.
25. Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:316-27.
26. Syed AM, Puthawala A, Sharma A, Gamie S, Londrc A, Cherlow JM, et al. High-dose-rate brachytherapy in the treatment of carcinoma of the prostate. Cancer Control 2001;8:511-21.
27. Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 2003;169:974-9; discussion 9-80.
28. Deger S, Boehmer D, Roigas J, Schink T, Wernecke KD, Wiegel T, et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol 2005;47:441-8.
29. Morton GC. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol) 2005;17:219-27.
30. Hoskin PJ, Bownes PJ, Ostler P, Walker K, Bryant L. High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiother Oncol 2003;68:285-8.
31. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Allen ZA, et al. Risk factors for the development of prostate brachytherapy related urethral strictures. J Urol 2006;175:1376-80; discussion 81.
32. Mullokandov E, Gejerman G. Analysis of serial CT scans to assess template and catheter movement in prostate HDR brachytherapy. Int J Radiat Oncol Biol Phys 2004;58:1063-71.
33. Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004;171:1098-104.
34. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283:354-60.
35. Yoshida K, Nose T, Shiomi H, Yoshioka Y, Fujita Y, Kuroda S, et al. New ambulatory implant technique of high-dose-rate interstitial brachytherapy for prostate cancer. Radiat Med 2006;24:595-9.